BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 151–200 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V6006
Binimetinib + EncorafenibCombination	Melanoma	Predictive	A	Supports Sensitivity Response	5	accepted	EID7287 In a phase 3 trial, patients with melanoma with BRAF V600E or V600K mutation were randomly assigned to encorafenib plus binimetinib or vemurafenib or encorafenib. mPFS was 14·9 months (95% CI 11·0-18·… (full text at CIViC) PMID 29573941 · Dummer et al., 2018 · Open in CIViC	civic
Refametinib	Melanoma	Predictive	C	Supports Resistance	2	accepted	EID1000 Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses adminis… (full text at CIViC) PMID 23434733 · Weekes et al., 2013 · Open in CIViC	civic
Trametinib	Melanoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1750 Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study. 322 eligible patients (281 with the V600E m… (full text at CIViC) PMID 22663011 · Flaherty et al., 2012 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Melanoma	Predictive	B	Supports Sensitivity Response	5	accepted	EID6180 Combination Dabrafenib and Trametinib treatment was assessed for adjuvant treatment of stage III resected BRAF V600 mutant melanoma in the COMBI-AD trial NCT01682083. Patients were treated with combin… (full text at CIViC) PMID 28891408 · Long et al., 2017 · Open in CIViC	civic
Cobimetinib + VemurafenibCombination	Melanoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID1422 In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progressio… (full text at CIViC) PMID 25265494 · Larkin et al., 2014 · Open in CIViC	civic
〃	Melanoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID6966 In this Phase 1b study, 129 patients with unresectable or metastatic melanoma were verified for BRAF V600 mutation using the cobas 4800 mutation test were selected who had progressed on vemurafenib (6… (full text at CIViC) PMID 25037139 · Ribas et al., 2014 · Open in CIViC	civic
BRAF V600E + EZH2 Y646FEZH2 BRAF1
JQEZ5	Melanoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID6952 Experiment with immunodeficient mice transplanted with melanoma cell lines indicates EZH2 inhibitor JQEZ5 might be effective in combination with a B-RAF inhibitor in RAF-mutant melanoma. PMID 27135738 · Souroullas et al., 2016 · Open in CIViC	civic
BRAF V600E13
MEK Inhibitor RO4987655	Melanoma	Predictive	B	Does Not Support Resistance	2	accepted	EID994 This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 17 patients with BRAF V600E melanoma, 4 achieved partial response, 5 experienced stable di… (full text at CIViC) PMID 24947927 · Zimmer et al., 2014 · Open in CIViC	civic
Pictilisib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID757 One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 wit… (full text at CIViC) PMID 25370471 · Sarker et al., 2015 · Open in CIViC	civic
Nutlin-3 + PLX4720Combination	Melanoma	Predictive	D	Supports Sensitivity Response
BRAF Wildtype1
MEK Inhibitor RO4987655	Melanoma	Predictive	B	Does Not Support Resistance	2	accepted	EID995 Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial … (full text at CIViC) PMID 24947927 · Zimmer et al., 2014 · Open in CIViC	civic
BRAF Fusion2
Sorafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID723 BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib. PMID 23890088 · Botton et al., 2013 · Open in CIViC	civic
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	2	accepted	EID724 A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines. PMID 23890088 · Botton et al., 2013 · Open in CIViC	civic
BRAF V600K4
Trametinib	Melanoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID2506 In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8m… (full text at CIViC) PMID 22663011 · Flaherty et al., 2012 · Open in CIViC	civic
Vemurafenib	Melanoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID1399 In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation. In this subgroup of treatment-naive patients, s… (full text at CIViC) PMID 24508103 · McArthur et al., 2014 · Open in CIViC	civic
〃	Melanoma	Predictive	B	Supports Sensitivity Response	3	accepted
BRAF Fusion1
Trametinib	Melanoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1663 Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acin… (full text at CIViC) PMID 26314551 · Ross et al., 2016 · Open in CIViC	civic
BRAF Fusion2
Trametinib	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID726 BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC	civic
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	3	accepted	EID725 BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib. PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID727 A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was "pan-negative" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was foun… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC	civic
AKT1 E17K + BRAF V600EAKT1 BRAF1
Uprosertib	Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID707 A melanoma cell line (M262) with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B in this study. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
BRAF V600E + PTEN LossBRAF PTEN1
Uprosertib	Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID708 Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
BRAF V600E + BRAF V600K1
Vemurafenib	Melanoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1410 Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E (n=122) or V600K (n=10) mutation. Confirmed overall response rate was 53% (95% confidence interval [CI], 44 t… (full text at CIViC) PMID 22356324 · Sosman et al., 2012 · Open in CIViC	civic
BRAF L505H2
Vemurafenib	Melanoma	Predictive	B	Supports Resistance	3	accepted	EID1669 In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutatio… (full text at CIViC) PMID 25515853 · Hoogstraat et al., 2015 · Open in CIViC	civic
〃	Melanoma	Predictive	D	Supports Resistance	4	accepted	EID1668 Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L… (full text at CIViC) PMID 24112705 · Wagenaar et al., 2014 · Open in CIViC	civic
BRAF L597R1
Vemurafenib	Melanoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID728 A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models. PMID 23715574 · Bahadoran et al., 2013 · Open in CIViC	civic
BRAF V600K + PREX2 R172IBRAF PREX21
Vemurafenib	Melanoma	Predictive	C	Supports Resistance	2	accepted	EID6268 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inh… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + NF1 LossBRAF NF11
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	3	accepted	EID90 In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors. PMID 24576830 · Nissan et al., 2014 · Open in CIViC	civic
BRAF V600E + KRAS G12DBRAF KRAS1
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	2	accepted	EID3957 In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600D2
Vemurafenib	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID4488 In an in vitro study, WM2664, a BRAF V600D expressing cell line, demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by … (full text at CIViC) PMID 18287029 · Tsai et al., 2008 · Open in CIViC	civic
〃	Melanoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID4489 In an in vitro study, the WM2664 and WM239A cell lines expressing BRAF V600D were associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. S… (full text at CIViC) PMID 20551065 · Yang et al., 2010 · Open in CIViC	civic
BRAF V600E + PIK3R2 N561DBRAF PIK3R21
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	3	accepted	EID4783 An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600 + PTEN UnderexpressionBRAF PTEN1
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	4	accepted	EID6271 An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PTEN and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that PTEN knockdown cells (achieved via … (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + PIK3CA OverexpressionBRAF PIK3CA1
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	2	accepted	EID6275 An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-expr… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF Amplification + BRAF V600E + BRAF V600K1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6262 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + NRAS MutationBRAF NRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6263 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + KRAS MutationBRAF KRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6264 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF intron 10 rearrangement1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	3	accepted	EID6400 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF intron 9 rearrangement1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	3	accepted	EID6401 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Bevacizumab	US FDA	—	Efficacy supplement 2006-10-11 (see label)	approved	Oct 11, 2006	openfda
Bevacizumab	US FDA	—	Efficacy supplement 2006-06-20 (see label)	approved	Jun 20, 2006	openfda
Bevacizumab	US FDA	—	Efficacy supplement 2005-09-29 (see label)	approved	Sep 29, 2005	openfda
Bevacizumab	US FDA	Malignant Colorectal Neoplasm	Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 551–600 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03944772	Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)(ORCHARD)	active not recruiting	Phase 2	247	AstraZenecaINDUSTRY	9	Jan 30, 2025	clinicaltrials
NCT05504278	Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation	recruiting	Phase 1	144	Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY	1	Jan 27, 2025	clinicaltrials
NCT06788366	AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer	recruiting	—	2,000	IRCCS San RaffaeleOTHER	1	Jan 23, 2025	clinicaltrials
NCT06782685	Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV	recruiting	Phase 1 / Phase 2	138	Dai, GuanghaiOTHER	1	Jan 20, 2025	clinicaltrials
NCT06607276	Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE(ACHIEVE)	recruiting	Phase 2	122	The First Affiliated Hospital with Nanjing Medical UniversityOTHER	1	Jan 16, 2025	clinicaltrials
NCT06775275	A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC	recruiting	Phase 2	60	The First Affiliated Hospital of Guangzhou Medical UniversityOTHER	1	Jan 15, 2025	clinicaltrials
NCT03709680	Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors	active not recruiting	Phase 2	128	PfizerINDUSTRY	14	Jan 14, 2025	clinicaltrials
NCT04440735	A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors	active not recruiting	Phase 1 / Phase 2	125	Kahr MedicalINDUSTRY	1	Jan 9, 2025	clinicaltrials
NCT04295317	PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery	active not recruiting	Phase 2	65	Shanghai Zhongshan HospitalOTHER	1	Jan 3, 2025	clinicaltrials
NCT06746870	A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer	not yet recruiting	Phase 2	148	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER	0	Dec 24, 2024	clinicaltrials
NCT05462613	Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer(REPROGRAM-02)	recruiting	Phase 2 / Phase 3	446	Centre Hospitalier Universitaire de BesanconOTHER	1	Dec 20, 2024	clinicaltrials
NCT06739395	Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion	recruiting	Phase 2	300	Tianjin Medical University Second HospitalOTHER	1	Dec 18, 2024	clinicaltrials
NCT06735326	Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer	recruiting	Phase 2	105	Qilu Hospital of Shandong UniversityOTHER	1	Dec 16, 2024	clinicaltrials
NCT06718309	Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC	recruiting	Phase 2	40	First People's Hospital of HangzhouOTHER	1	Dec 5, 2024	clinicaltrials
NCT05824975	A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)	recruiting	Phase 1 / Phase 2	358	GI Innovation, Inc.INDUSTRY	2	Nov 25, 2024	clinicaltrials
NCT02919787	Nordic Pancreatic Cancer Trial (NorPACT) - 1	active not recruiting	Phase 2 / Phase 3	140	Oslo University HospitalOTHER	4	Nov 20, 2024	clinicaltrials
NCT03845166	A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001)	active not recruiting	Phase 1	325	ExelixisINDUSTRY	10	Nov 19, 2024	clinicaltrials
NCT05979818	Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer(BRIO)	recruiting	Phase 1	6	Second Xiangya Hospital of Central South UniversityOTHER	1	Nov 19, 2024	clinicaltrials
NCT04294264	TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer	active not recruiting	Phase 2	50	Rutgers, The State University of New JerseyOTHER	1	Nov 18, 2024	clinicaltrials
NCT06532344	An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer	active not recruiting	Phase 1	32	Ono Pharmaceutical Co., Ltd.INDUSTRY	1	Nov 14, 2024	clinicaltrials
NCT06411600	Combination Therapy for BRAF-V600E Metastatic CRCm(BRAVE)	recruiting	Phase 2	94	Vall d'Hebron Institute of OncologyOTHER	1	Nov 8, 2024	clinicaltrials
NCT05468242	Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy	recruiting	Phase 2	116	Sun Yat-sen UniversityOTHER	1	Oct 30, 2024	clinicaltrials
NCT06650709	NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study(NEOCATS)	not yet recruiting	Phase 2	40	British Columbia Cancer AgencyOTHER	0	Oct 23, 2024	clinicaltrials
NCT04322890	Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation(PIKACHU)	recruiting	Phase 2	6,000	Hunan Province Tumor HospitalOTHER	1	Oct 22, 2024	clinicaltrials
NCT03635021	Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer(CR-SEQUENCE)	active not recruiting	Phase 3	419	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER	1	Oct 21, 2024	clinicaltrials
NCT04547166	A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)	recruiting	Phase 2 / Phase 3	568	Shanghai Henlius BiotechINDUSTRY	2	Oct 17, 2024	clinicaltrials
NCT05501665	Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	recruiting	Phase 1 / Phase 2	25	Vanderbilt-Ingram Cancer CenterOTHER	1	Oct 17, 2024	clinicaltrials
NCT06184698	Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer	recruiting	Phase 2	173	Hebei Medical University Fourth HospitalOTHER	1	Oct 9, 2024	clinicaltrials
NCT04117945	Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer	active not recruiting	Phase 2	22	Academic and Community Cancer Research UnitedOTHER	1	Sep 27, 2024	clinicaltrials
NCT05295212	Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB	recruiting	Phase 2	120	Hunan Province Tumor HospitalOTHER	1	Sep 19, 2024	clinicaltrials
NCT06493760	A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients	recruiting	Phase 2	130	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY	1	Sep 19, 2024	clinicaltrials
NCT06540261	The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer	active not recruiting	Phase 1	65	Ono Pharmaceutical Co., Ltd.INDUSTRY	1	Sep 19, 2024	clinicaltrials
NCT06571461	Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer	not yet recruiting	Phase 3	408	CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY	0	Aug 27, 2024	clinicaltrials
NCT05654454	A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer	recruiting	Phase 3	620	Mabscale, LLCINDUSTRY	1	Aug 16, 2024	clinicaltrials
NCT06557096	CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC	not yet recruiting	Early Phase 1	100	Second Affiliated Hospital of Nanchang UniversityOTHER	0	Aug 16, 2024	clinicaltrials
NCT06341296	Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer	recruiting	Phase 2	86	West China HospitalOTHER	1	Aug 12, 2024	clinicaltrials
NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer(EROS)	recruiting	—	80	Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER	1	Aug 9, 2024	clinicaltrials
NCT06547385	Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer	active not recruiting	Phase 1	40	Ono Pharmaceutical Co., Ltd.INDUSTRY	1	Aug 9, 2024	clinicaltrials
NCT06531291	Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation	not yet recruiting	Phase 2	80	RenJi HospitalOTHER	1	Jul 31, 2024	clinicaltrials
NCT06509126	Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer(IMPROVE-2)	recruiting	Phase 3	500	National Cancer Institute, NaplesOTHER	1	Jul 19, 2024	clinicaltrials
NCT06332170	ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors	recruiting	Phase 1	610	Hansoh BioMedical R&D CompanyINDUSTRY	1	Jul 18, 2024	clinicaltrials
NCT06336707	HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors	recruiting	Phase 1	1,048	Hansoh BioMedical R&D CompanyINDUSTRY	1	Jul 18, 2024	clinicaltrials
NCT06504901	Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases	not yet recruiting	—	30	The First Affiliated Hospital with Nanjing Medical UniversityOTHER	0	Jul 17, 2024	clinicaltrials
NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE)	recruiting	Phase 2	250	Helsinki University Central HospitalOTHER	1	Jul 15, 2024	clinicaltrials
NCT05462236	MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer	recruiting	Phase 2	120	AUM Biosciences Pte LtdOTHER	1	Jul 9, 2024	clinicaltrials
NCT04143607	ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC	active not recruiting	Phase 3	337	Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY	1	Jun 14, 2024	clinicaltrials
NCT06446388	Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors	not yet recruiting	Phase 2	360	Qilu Pharmaceutical Co., Ltd.INDUSTRY	1	Jun 6, 2024	clinicaltrials
NCT03351296	Two Chemotherapy Regimens Plus or Minus Bevacizumab(BETTER2)	active not recruiting	Phase 2	140	Gustave Roussy, Cancer Campus, Grand ParisOTHER	1	May 8, 2024	clinicaltrials
NCT05859217	A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)(Cabatezo-1)	not yet recruiting	Phase 2	40	Jun Zhang, MD, PhDOTHER	1	May 8, 2024	clinicaltrials
NCT06394713	A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors	not yet recruiting	Phase 1 / Phase 2	60	Qilu Pharmaceutical Co., Ltd.INDUSTRY	0	May 1, 2024	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)